Article: CANTAB PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS

Article: Cantab Pharmaceuticals Reports Second Quarter Results
PR Newswire;  August 12, 1996 ;     700+ words ... ... equity financing in July, Cantab is now in the strongest cash ... John Collins, Chairman of Cantab. "During the last several ... potential cancer targets in the DISC Oncology program have been identified ... D., Research Director of Cantab, has been appointed to Cantab ...

Article: Cantab Pharmaceuticals Reports Third Quarter Results
PR Newswire;  November 29, 1996 ;     700+ words ... ... Chief Executive Officer of Cantab. "In particular, the encouraging ... volunteers was commenced. -- Cantab's U.K. Phase I clinical ... Preclinical development for first DISC Oncology candidate has begun. -- DISC ... Chief Executive Officer of Cantab. -- Dr. Paul Haycock, former ...

Article: Cantab Pharmaceuticals Reports 1997 Second Quarter ...
PR Newswire;  August 5, 1997 ;     700+ words ... ... expected to be complete by the end of 1997. -- Cantab's DISC Oncology program in cancer immunotherapy is scheduled ... viruses expressing immunomodulator genes, Cantab now has two DISC Oncology product candidates in preclinical development ...

Article: CANTAB RECEIVES U.K. REGULATORY APPROVAL TO BEGIN CLINICAL ...
PR Newswire;  July 15, 1996 ;     700+ words ... ... delivery. In the vaccine area, Cantab has focused its efforts particularly ... Within the gene delivery area, Cantab initiated, during 1995, its DISC Oncology program, which is potentially ... DISC Gene therapy program. Cantab Pharmaceuticals plc, based ...

Article: Cantab Reports First Quarter Financial Results And Solid ...
PR Newswire;  May 25, 1998 ;     700+ words ... ... the second half of 1998. -- Cantab presented positive safety and ... on Infectious Diseases. -- Cantab commenced Phase I trial of ... second half of 1998. -- Our DISC Oncology program is advancing, as new ... and shingles. -- Phogen, Cantab's joint venture with Marie ...

Article: Cantab Reports Second Quarter Results; Further Progress ...
PR Newswire;  August 11, 1998 ;     700+ words ... ... developments. TA-CIN and DISC Oncology programs have also made ... development highlights to Cantab's achievements in the ... Phase I/II trial in the DISC Oncology programme. Promising ... technology. In addition, Cantab also reported that, with ...

Article: Cantab Pharmaceuticals Reports Fourth Quarter Results
PR Newswire;  March 19, 1997 ;     700+ words ... ... England, March 19 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY ... additional 115,000 pounds received under Cantab's existing research agreement with Pfizer Animal Healthcare Group. In 1995, Cantab's revenues came mainly from the Pfizer ...